
MDxHealth SA (MDXH) Stock Forecast & Price Target
MDxHealth SA (MDXH) Analyst Ratings
Bulls say
MDxHealth is a molecular diagnostics lab with a strong focus on prostate testing, which currently generates the majority of its revenue from the United States. Its innovative tests, such as the SelectMDx and ConfirmMDx, offer highly personalized and actionable information to physicians and have the potential to significantly reduce the number of unnecessary biopsies and associated risks. With a solid track record of successful acquisitions and new partnerships, MDxHealth is well-positioned for continued growth and is expected to generate significant cost savings for the U.S. healthcare system.
Bears say
MDxHealth is facing significant challenges in the wake of a Q1 earnings miss and a surprise material guide down for 2026. The company is discontinuing its UTI test, which caught investors off guard, and is facing a reimbursement issue that could result in a recoupment payment of $10M from Medicare. Additionally, there is uncertainty around the company's ability to access new debt and its current debt is fully borrowed, making it imperative for MDxHealth to control costs and achieve positive free cash flow in 2027. Hence, the outlook for the stock is negative, with a lowered price target of $1.50.
This aggregate rating is based on analysts' research of MDxHealth SA and is not a guaranteed prediction by Public.com or investment advice.
MDxHealth SA (MDXH) Analyst Forecast & Price Prediction
Start investing in MDxHealth SA (MDXH)
Order type
Buy in
Order amount
Est. shares
0 shares